Pinebridge Investments L.P. grew its position in shares of Luminex Corporation (NASDAQ:LMNX) by 8.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,266 shares of the medical instruments supplier’s stock after purchasing an additional 405 shares during the quarter. Pinebridge Investments L.P.’s holdings in Luminex Corporation were worth $111,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. New York State Common Retirement Fund increased its holdings in Luminex Corporation by 1.4% in the 2nd quarter. New York State Common Retirement Fund now owns 44,200 shares of the medical instruments supplier’s stock worth $934,000 after acquiring an additional 599 shares in the last quarter. Thrivent Financial For Lutherans increased its holdings in Luminex Corporation by 14.4% in the 2nd quarter. Thrivent Financial For Lutherans now owns 24,170 shares of the medical instruments supplier’s stock worth $510,000 after acquiring an additional 3,050 shares in the last quarter. Elk Creek Partners LLC increased its holdings in Luminex Corporation by 9.8% in the 2nd quarter. Elk Creek Partners LLC now owns 766,935 shares of the medical instruments supplier’s stock worth $16,198,000 after acquiring an additional 68,519 shares in the last quarter. BlackRock Inc. increased its holdings in Luminex Corporation by 14.1% in the 2nd quarter. BlackRock Inc. now owns 5,776,500 shares of the medical instruments supplier’s stock worth $121,999,000 after acquiring an additional 713,436 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Luminex Corporation by 15.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 259,057 shares of the medical instruments supplier’s stock worth $5,471,000 after acquiring an additional 35,260 shares in the last quarter. 77.95% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on LMNX shares. TheStreet lowered shares of Luminex Corporation from a “b” rating to a “c+” rating in a report on Monday, August 7th. BidaskClub lowered shares of Luminex Corporation from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research lowered shares of Luminex Corporation from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, ValuEngine lowered shares of Luminex Corporation from a “hold” rating to a “sell” rating in a report on Saturday, July 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.40.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/08/pinebridge-investments-l-p-purchases-405-shares-of-luminex-corporation-lmnx.html.

Shares of Luminex Corporation (LMNX) opened at 20.56 on Friday. Luminex Corporation has a one year low of $17.64 and a one year high of $23.62. The stock has a market cap of $906.10 million, a price-to-earnings ratio of 63.65 and a beta of 0.29. The company has a 50-day moving average of $19.65 and a 200 day moving average of $19.88.

Luminex Corporation (NASDAQ:LMNX) last released its earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The company had revenue of $76.50 million during the quarter, compared to the consensus estimate of $75.45 million. During the same quarter last year, the company earned $0.33 earnings per share. Luminex Corporation’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, equities analysts forecast that Luminex Corporation will post $0.53 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 22nd will be issued a $0.06 dividend. This represents a $0.24 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, September 21st. Luminex Corporation’s dividend payout ratio (DPR) is currently 75.00%.

In other news, Director Robert J. Cresci sold 19,631 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total value of $372,596.38. Following the completion of the transaction, the director now owns 260,358 shares in the company, valued at $4,941,594.84. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 6.90% of the company’s stock.

About Luminex Corporation

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Corporation (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Receive News & Stock Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related stocks with our FREE daily email newsletter.